Linda Wagner-Weiner to Treatment Outcome
This is a "connection" page, showing publications Linda Wagner-Weiner has written about Treatment Outcome.
Connection Strength
0.208
-
Pediatric anti-NMDA receptor encephalitis with catatonia: treatment with electroconvulsive therapy. Pediatr Rheumatol Online J. 2019 Feb 18; 17(1):8.
Score: 0.059
-
Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome. Arthritis Rheumatol. 2025 May; 77(5):606-614.
Score: 0.022
-
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). 2025 Apr; 77(4):504-512.
Score: 0.022
-
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024 Oct 21; 83(11):1561-1571.
Score: 0.022
-
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. J Rheumatol. 2021 07; 48(7):1073-1081.
Score: 0.017
-
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis Rheumatol. 2019 03; 71(3):451-459.
Score: 0.015
-
Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. Pediatr Rheumatol Online J. 2018 Oct 22; 16(1):65.
Score: 0.014
-
Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. Arthritis Rheumatol. 2018 09; 70(9):1508-1518.
Score: 0.014
-
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014 Mar; 73(3):557-66.
Score: 0.010
-
Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012 Jan; 64(1):285-96.
Score: 0.009
-
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003 Feb; 30(2):394-400.
Score: 0.005